This session will explore the use of biomarker technology to support the diagnostic assessment of patients with Alzheimer’s disease (AD) in clinical practice.
Dr Chineze Ivenso will present on the development of memory assessment services in Wales, which offer in-house access to biomarker investigations.
Dr Jemma Hazan will focus on the application of AD blood biomarkers in memory services. She will present on the ADAPT: Alzheimer’s disease Diagnosis And Plasma P-Tau217 Study, a national randomised controlled trial to determine the real-life clinical utility and cost-effectiveness of this blood biomarker in memory services.
This session with be chaired by Professor Robert Howard who will offer insights into the future directions of AD blood biomarker in diagnostic assessments.
Learning objectives
By attending this session you will:
- Explore the development of memory services that provide access to Alzheimer's disease biomarker investigations, such as cerebrospinal fluid analysis, FDG PET, and Amyloid PET scans
- Learn about the appropriate use and implementation of amyloid-PET in real-world clinical settings and how this may inform the introduction of blood-based biomarker technologies
- Gain insights into the evaluation of the clinical utility of Alzheimer's disease blood biomarkers in memory services.
Speakers
Chair: Professor Robert Howard, UCL, London Dr Chineze Ivenso, Aneurin Bevan University Health Board, Newport
Dr Jemma Hazan, UCL, London
Availability
This webinar is part of the Congress webinar 2025 package. If you attended all four days of Congress, you will have access to these as part of your Congress package. Otherwise the Congress webinar 2025 package can be purchased below.
